Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019.
Autor: | Razonable RR; Mayo Clinic, Rochester, MN, USA., Ganesh R; Mayo Clinic, Rochester, MN, USA., Bishop RK; Mayo Clinic Health System-Franciscan Healthcare, La Crosse, WI, USA., Culbertson TL; Mayo Clinic Health System, Mankato, MN, USA., Destro Borgen M; Mayo Clinic, Rochester, MN, USA., Hedin MC; Mayo Clinic, Rochester, MN, USA., Hopkins LH; Mayo Clinic Health System, Mankato, MN, USA., Jackson TA; Mayo Clinic Health System, Eau Claire, WI, USA., Larsen JJ; Mayo Clinic, Rochester, MN, USA., Matoush JA; Mayo Clinic, Rochester, MN, USA., Moehnke DE; Mayo Clinic, Rochester, MN, USA., Olson SM; Mayo Clinic Health System, Owatonna, MN, USA., Peterson KM; Mayo Clinic Health System, Albert Lea, MN, USA., Rosedahl J; Mayo Clinic, Rochester, MN, USA., Philpot LM; Mayo Clinic, Rochester, MN, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of patient experience [J Patient Exp] 2022 Jun 23; Vol. 9, pp. 23743735221105673. Date of Electronic Publication: 2022 Jun 23 (Print Publication: 2022). |
DOI: | 10.1177/23743735221105673 |
Abstrakt: | Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19. Competing Interests: Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© The Author(s) 2022.) |
Databáze: | MEDLINE |
Externí odkaz: |